Considering a number of people on here were saying that the reason that A2m were not chasing temporary FDA approval was that they didn't have the inventory, one would expect that a beat was the only possible scenario that would reflect this view, but that narrative only suits when you wish to pursue a certain argument i guess.
In regards to the new packaging and formulation, it was never mentioned about it being a suprise but simply that it is a good chance to inform the market that these things had occurred and a chance to say to the broker concerns published in this regard that the formulation issue is addressed.
Funny how in one moment people here tote about the media is biased, only interested in certain narratives, the next it is acceptable for that to be the information source for shareholders. One feels that most shareholders would feel that hearing things like new formulation launched, FDA application is probably worth more than a second hand news source and is actually worthy off a company update every now and then, after all it is all part of disclosure and considering that A2m currently have a class action in this regard one would have thought that erring on the give a bit more info rather than give none might have been a prudent course of action.
But hey each to there own, i see another downgrade issued today so the people that have a little more influence than a hotcopper forumn appear to be disagreeing with the rusties.
A2M Price at posting:
$4.45 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)